Bernstein analyst William Pickering raised the firm’s price target on Arrowhead to $32 from $27 and keeps a Market Perform rating on the shares. The firm notes that there is a lot happening – CV phase 3 starts, pulmonary data in multiple indications, and new trials kicking off in muscle and adipose, to name a few. But it doesn’t expect most of these to actually move the stock – asthma PFT data is the one Bernstein feels best about, but even good data won’t refute concern that the space is too crowded, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARWR:
- Arrowhead applies for clearance to begin Phase 1/2a trial of RNAi therapeutic
- Bank of America Says the S&P 500 Will Hit a New Record High in 2024 — Here Are 2 Stocks to Play That Bullish Sentiment
- Biotech Alert: Searches spiking for these stocks today
- GM upgraded, Lululemon downgraded: Wall Street’s top analyst calls
- Arrowhead initiated with a Buy, $29 price target at BofA